BRIEF-GSK starts phase III of coronary drug test

June 5 Thu Jun 5, 2014 10:04am EDT

Related Topics

June 5 (Reuters) - GlaxoSmithKline Plc :

* GSK announces start of phase III cardiovascular outcomes study with Losmapimod in patients with acute coronary syndrome

* Phase III study will assess whether Losmapimod can reduce risk of a subsequent cardiac event when administered orally twice a day for a period of three months immediately after presentation with an acute coronary syndrome Further company coverage:

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.